Pharmacists in Paulsboro, NJ Accepting Medicare
6 Pharmacists found. Showing 1 - 6
 Ashley Ebner Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 231 W Broad St, Paulsboro, NJ 08066 Phone: 856-423-7788 |
Ms. Anna Marie M Bailey, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 231 W Broad St, Paulsboro, NJ 08066 Phone: 856-423-7788 |
Ms. Holly Roche, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1 E Broad St, Paulsboro, NJ 08066 Phone: 856-224-0533 |
Andrea Helen Villare Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 231 W Broad St, Paulsboro, NJ 08066 Phone: 856-423-7788 |
Ginny Li Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1 E Broad St, Paulsboro, NJ 08066 Phone: 856-224-0533 |
 Mr. Vipulkumar T Patel, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1 E Broad St, Paulsboro, NJ 08066 Phone: 856-224-0533 Fax: 856-224-1845 |
News Archive
UH GCSW to host Houston, Leading America's Future round table discussion
The University of Houston (UH) Graduate College of Social Work (GCSW) will host, "Houston, Leading America's Future," a round table discussion addressing what can be done today to ensure the success of Houston's multicultural society at 4 p.m., Friday, Feb. 24 at the UH GCSW building, Room 102.
Genetic study helps investigators solve medical mysteries
The mystery began in 1976. Adolfo Pampena was diagnosed with a rare form of cancer that caused a strange combination of symptoms and was associated with the occurrence of multiple tumours in his stomach and colon. His medical team was stumped and was unable to answer the most important questions for him and his family: the cause of his disease and the risk for future generations.
Research study reveals that high-fructose corn syrup is used as a sweetener in beverages
Researchers have established the conditions that foster formation of potentially dangerous levels of a toxic substance in the high-fructose corn syrup (HFCS) often fed to honey bees.
Researchers report outcomes of salvage low dose RT brachytherapy after EBRT for prostate cancer
Researchers involved in the phase II NRG Oncology RTOG 0526 trial studying low dose rate (LDR) prostate brachytherapy (BT) following local recurrence (LR) after external beam radiotherapy (EBRT) for patients with low-to-intermediate risk prostate cancer reported late Grade 3 gastrointestinal and genitourinary adverse events (AEs) occurring in 14% of trial participants.
Impax sells U.S. rights to Daraprim brand for $55 million to Turing Pharmaceuticals
Impax Laboratories, Inc. today announced that it has sold its U.S. rights to the Daraprim brand to Turing Pharmaceuticals AG for approximately $55 million.
› Verified 4 days ago